Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Restriction Enzymes01:11

Restriction Enzymes

35.7K
Restriction enzymes are bacterial enzymes used to cut DNA in a sequence-specific manner. To cleave DNA, they bind to specific palindromic sequences called restriction sites. Such palindromic DNA sequences or inverted repeats are commonly found in regions of functional significance, such as the origin of replication, gene operator sites, and regions containing transcription termination signals.
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
35.7K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

488
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
488
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

493
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
493
Cancer02:18

Cancer

53.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.7K
What is Cancer?02:12

What is Cancer?

14.0K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer.

Journal of experimental & clinical cancer research : CR·2026
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.

Annals of the rheumatic diseases·2026
Same author

High-Affinity Human Germline and Mutated Autoantibodies Commonly Cross-React to Self-Antigens in 5 Subgroups of Autoimmune Encephalitis.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026

Related Experiment Video

Updated: Jan 23, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
09:45

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity

Published on: January 29, 2018

9.8K

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome.

Uta M Demel1,2,3, Anna Meurer1,2, Badeel Kh Q Zaghla1

  • 1Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|January 22, 2026
PubMed
Summary

Aberrant SUMOylation in cancer restricts anti-tumor immunity by limiting peptide presentation. Inhibiting SUMOylation restores immune surveillance and enhances cancer immunotherapy effectiveness.

Keywords:
antigen presentationcancer immunotherapyimmunopeptidomemhc‐isumo

More Related Videos

In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells
09:40

In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells

Published on: November 2, 2017

7.7K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K

Related Experiment Videos

Last Updated: Jan 23, 2026

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity
09:45

In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity

Published on: January 29, 2018

9.8K
In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells
09:40

In Vivo Detection and Analysis of Rb Protein SUMOylation in Human Cells

Published on: November 2, 2017

7.7K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.8K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • SUMOylation (Small Ubiquitin-like Modifier) is crucial for maintaining anti-tumor immune responses.
  • Aberrant SUMOylation is a characteristic feature of cancer, impacting immune evasion.
  • Understanding SUMOylation's role in the tumor-immune synapse is vital for developing new cancer therapies.

Purpose of the Study:

  • To investigate the impact of activated SUMOylation on the tumor-immune synapse.
  • To identify how SUMOylation affects the presentation of peptides by HLA class I molecules.
  • To explore SUMOylation inhibition as a potential cancer immunotherapy strategy.

Main Methods:

  • HLA class-I-targeted ligandomics to analyze the immunopeptidome.
  • Assessing immunoproteasome activity and TAP1 transporter function.
  • Evaluating the effects of pharmacological SUMOylation inhibition in cancer models.

Main Results:

  • Activated SUMOylation restricts the immunopeptidome landscape, including neoantigens, aiding cancer immune evasion.
  • SUMOylation impairs immunoproteasome function and alters TAP1 binding, limiting peptide diversity.
  • Pharmacological inhibition of SUMOylation unmasks targetable peptides, increases tumor cell susceptibility to T cell killing, and modulates the immune cell landscape.

Conclusions:

  • SUMOylation is a key regulator of adaptive anti-tumor immunity.
  • Inhibiting SUMOylation enhances immunogenic peptide presentation, improving cancer immunotherapy efficacy.
  • Targeting SUMOylation presents a promising strategy to overcome cancer immune evasion.